HRAS and urinary bladder cancer: Previous studies indicated that the histone deacetylase inhibitor FR901228 selectively induces ROS production in Hras-expressing J82 bladder cancer cells versus the parental cells [80]; ROS induction can render both mutant and wild-type Kras pancreatic cancer cells susceptible to Ad.mda-7/IL-24-induced apoptosis [81].